Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995729 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
A Phase 1 study of Acute Treatment of Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 13
- Study locations
NCT06995729 is a Phase 1 study of Acute Treatment of Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 16 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT06995729, a Phase 1 study of Acute Treatment of Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: * Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs. The study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine. Participants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.
Conditions Studied
Interventions
- DRUG Zavegepant
Study Locations (13)
North Carolina
- Accellacare - Piedmont - Statesville
- Accellacare of Piedmont HealthCare - Statesville
- Accellacare US Inc. - Winston-Salem
Utah
- Wasatch Clinical Research, LLC - Salt Lake City
- Granger Medical Holladay - Holladay Clinic - Salt Lake City
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Velocity Clinical Research, Washington DC - Washington D.C.
Georgia
- Coastal Heritage Clinical Research - Hinesville
Minnesota
- Clinical Research Institute - Minneapolis
Nebraska
- Children's Hospital & Medical Center - Omaha
New York
- True North Neurology - Port Jefferson Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2027-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06995729
The ClinicalTrials.gov registry entry for NCT06995729 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Treatment of Migraine appearing as the primary indexed condition, and to 1 intervention - of which Zavegepant is the first listed.
NCT06995729 reports 13 study locations spanning 10 distinct geographic areas - top geographies include North Carolina, Utah, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06995729 about?
NCT06995729 is a clinical study titled "A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine". The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participan...
What is the current status of trial NCT06995729?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-05-16. Estimated completion is 2027-08-12.
What conditions does trial NCT06995729 study?
This clinical trial studies the following conditions: Acute Treatment of Migraine.
What interventions are being tested in trial NCT06995729?
The interventions under investigation include: Zavegepant (DRUG).
Who is sponsoring clinical trial NCT06995729?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995729 being conducted?
This trial has 13 study locations across Arkansas, District of Columbia, Georgia, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Treatment of Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.